Canada· CA-DIN-00463221
LYSODREN
A mitotane product containing mitotane, registered in Canada by HRA PHARMA RARE DISEASES. The same ATC class is registered in 15 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Mitotane is registered in 15 of 19 countries.
Countries holding a registration under ATC L01XX23 (mitotane), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 10 of them publish a price we can compare per daily dose
Mitotane · ATC L01XX23
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- MITOTANE
- Manufacturer
- HRA PHARMA RARE DISEASES
- Country
- Canada (CA)
- ATC code
- L01XX23
- ATC class
- Mitotane
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
376 interactions on record for mitotane.
Graded by severity as the source publishes them — 193 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mitotane · interactions on record
376 records
- 193 severe
- 138 moderate
- 30 minor
- 15 info
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- NaldemedineA06AH05severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mitotane in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLysodrenHRA Pharma Rare Diseases
- United KingdomLysodren 500mg tabletsEsteve RD UK & Ireland Ltd
- FinlandLysodrenEsteve Pharmaceuticals, S.A
- FranceLYSODREN 500 mg, compriméESTEVE PHARMACEUTICALS (ESPAGNE)
- CzechiaLYSODRENEsteve Pharmaceuticals S.A., Barcelona
- NetherlandsLysodren 500 mg tablettenEsteve Pharmaceuticals S.A.
- NorwayLysodrenEsteve Pharmaceuticals S.A
- PolandLysodrenHRA Pharma Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lysodren
- Liechtenstein · Lysodren
- Norway · Lysodren
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/52d1c885-ef9b-4dcf-a36a-fd233d2c5e20 GET /v1/drugs/52d1c885-ef9b-4dcf-a36a-fd233d2c5e20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "00463221",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01XX23",
"schedule": [
"Prescription"
],
"drug_code": "3348",
"strengths": [
"500 MG"
],
"ahfs_class": null,
"substances": [
"MITOTANE"
],
"product_categorization": null
}See everything about mitotane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.